AlphaMark Advisors LLC Reduces Holdings in Eli Lilly and Company (NYSE:LLY)

AlphaMark Advisors LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 20.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 638 shares of the company’s stock after selling 160 shares during the period. AlphaMark Advisors LLC’s holdings in Eli Lilly and Company were worth $565,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Capital Planning LLC purchased a new position in Eli Lilly and Company during the first quarter worth $262,000. CHURCHILL MANAGEMENT Corp purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $6,916,000. M&G Plc acquired a new position in Eli Lilly and Company in the 1st quarter valued at about $8,896,000. BTC Capital Management Inc. purchased a new position in Eli Lilly and Company in the 1st quarter valued at about $1,432,000. Finally, High Net Worth Advisory Group LLC boosted its stake in shares of Eli Lilly and Company by 1.4% during the 1st quarter. High Net Worth Advisory Group LLC now owns 4,919 shares of the company’s stock worth $3,827,000 after purchasing an additional 67 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on LLY. Bank of America upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Barclays upped their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Guggenheim raised their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $986.00.

Eli Lilly and Company Stock Up 0.1 %

NYSE LLY opened at $917.18 on Friday. The business has a 50 day moving average price of $920.70 and a two-hundred day moving average price of $856.27. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market cap of $871.69 billion, a PE ratio of 135.08, a P/E/G ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, sell-side analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.